24/7 Market News Snapshot 22 October, 2024 – Immunic, Inc. Common Stock (NASDAQ:IMUX)

October 22, 2024

DENVER, Colo., 22 October, 2024 (247marketnews.com) – (NASDAQ:IMUX) are discussed in this article.
Immunic, Inc. (IMUX) is experiencing a notable surge in pre-market trading, with shares currently valued at $1.912—an impressive increase of 23.35% compared to the prior close of $1.550. This upward momentum is further emphasized by a strong trading volume of 830.56K shares, reflecting heightened investor interest and optimism regarding the company’s future developments. This bullish sentiment may be attributed to positive recent news surrounding Immunic’s ongoing phase 3 ENSURE program focused on vidofludimus calcium (IMU-838) for the treatment of relapsing multiple sclerosis (RMS).

The Independent Data Monitoring Committee (IDMC) recently conducted an interim futility analysis of the ENSURE program and confirmed that the study has met its predefined success criteria. Consequently, the IDMC has recommended that the trials continue as planned, supporting the existing sample size and study design. This pivotal program includes two multicenter, randomized trials with an anticipated recruitment of approximately 1,050 adult participants diagnosed with active RMS. Key endpoints will assess the time to first relapse, measures of disability progression, and neurological changes associated with the treatment.

Immunic’s Chief Medical Officer, Dr. Andreas Muehler, highlighted the significance of the IDMC’s findings, which align with the company’s initial assumptions. Dr. Daniel Vitt, the CEO, expressed optimism about the interim results, viewing vidofludimus calcium as a possible game changer for patients suffering from multiple sclerosis, thereby addressing longstanding unmet needs in therapeutic options.

Looking ahead, Immunic is also preparing for the forthcoming readout of the phase 2 CALLIPER trial in April, targeting progressive forms of multiple sclerosis. If proven effective, vidofludimus calcium could establish itself as a leading oral treatment in this demanding therapeutic area. As the company continues to advance its clinical endeavors, it remains dedicated to delivering innovative solutions for chronic inflammatory and autoimmune diseases.

Related news for (IMUX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.